Category: sixteen

FIDIA PHARMA USA INC. Introduces New Product Packaging for HYALO GYN® Featuring a Fresh, Feminine Look PARSIPPANY, N.J., Dec. 7, 2016 – Many women suffer silently from the bothersome symptoms associated with vaginal dryness. Vaginal dryness can have many origins, including childbirth, breast-feeding, menopause, chemotherapy, oral contraceptive use and stress.1 Vaginal hydrating gels, such as […]

PARSIPPANY, N.J., Nov. 28, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, FIDIA PHARMA USA INC., introduces newly redesigned packaging for the vaginal hydrating gel, HYALO GYN®. While keeping its current formulation, HYALO GYN®’s new product packaging gives the […]

PARSIPPANY, NJ.(BUSINESS WIRE)— Fidia Pharma USA Inc., a wholly owned subsidiary of Fidia Farmaceutici S.p.A. a worldwide leader in the research development and manufacturing of HA based products, has announced that the Center for Medicare & Medicaid Services (“CMS”) has assigned its product HYMOVIS® a unique Healthcare Common Procedure Coding System (“HCPCS”) code, or J-Code. […]

A breakthrough in viscoelastic technology; Hymovis® is an excellent choice for the high-demand patient with OA of the knee PARSIPPANY, N.J., May 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., announced that Hymovis® (high molecular […]

Hymovis®, which is being launched in the U.S, is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties PARSIPPANY, N.J., February 25, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia […]